Adicet Bio’s (ACET) Neutral Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their neutral rating on shares of Adicet Bio (NASDAQ:ACET – Free Report) in a report published on Thursday,Benzinga reports. A number of other research firms have also commented ...
生物通10 小时
BCMA 靶向疗法治疗多发性骨髓瘤的新进展：2024 ASH 年会成果解读
综上所述，2024 ASH 年会展示的这些 BCMA 靶向疗法的临床试验结果令人振奋，为 MM 患者带来了新的希望。这些研究成果不仅进一步证实了 BCMA 靶向疗法在 MM 治疗中的有效性，还为不同阶段 MM ...